drug discovery | GenomeWeb

drug discovery

TwoXar will work with Stanford's Asian Liver Center to identify and validate computationally-derived drug candidates that target hepatocellular carcinomas.

Cyclica will soon begin testing a commercial version of its services software this summer ahead of a full launch planned for next year.

The partners will generate and analyze disease-specific gene expression data to identify likely drug candidates for rare skin diseases.

Under the terms of the agreement, Insilico Medicine will integrate unspecified data assets and the staff of Belgian bioinformatics company InSilico Screen.

TwoXar will use the funds to expand its engineering and commercial teams and  support partnerships focused on drug candidates for metabolic and neurological diseases.

NEW YORK (GenomeWeb News) – Microbiome company Second Genome today announced a deal with Johnson & Johnson's Janssen Biotech aimed at microbiome drug discovery.
Second Genome also announced it raised an additional $6.5 million in Series A financing.

NEW YORK (GenomeWeb News) – MyoKardia, a San Francisco-based drug startup, has been launched with $38 million in Series A financing from Third Rock Ventures.

Isogenica, Biolauncher, and Cresset Biomolecular Discovery will integrate expertise in peptide library design, evolutionary screening, next-generation sequencing, structural analysis, and molecular field-based computational chemistry into their new platform.

The collaboration combines Regulus' miRNA platform with UCSD's animal models of angiogenesis.

Pages

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.